Evaluated extensively
MONA has been tested in many settings, from a national screening programme to hospital eye clinics and primary care. Numerous peer-reviewed papers have been published about MONA, including 2 in Lancet journals. We stand strong on these clinical results.
Highlights from the Lancet papers
Diabetic retinopathy
The Lancet Digital Health, 2025
National screening programme: 202,886 screening encounters, 126,365 people, 8 AI systems compared.
- MONA had the highest specificity of the 8 systems: 95.7% in people with no retinopathy or maculopathy.
- Sensitivity greater than 96% for moderate to proliferative retinopathy.
- About 77% fewer encounters needed human grading.
Reference: Rudnicka AR, Shakespeare R, Chambers R, et al. Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme. The Lancet Digital Health 2025;7:100914.
Glaucoma
The Lancet Primary Care, 2026
Primary-care study: 671 adults screened, added to an existing diabetic eye screening visit.
- Sensitivity: MONA 78% vs experts 75%, as many cases found as experts.
- Specificity: MONA 10% vs experts 18%, about half as many referrals and hospital visits.
Reference: Lima-Cabrita A, Wehbi Z, Pargana J, et al. Artificial intelligence-based glaucoma screening in primary care: a cross-sectional study and economic viability analysis of an ongoing trial. The Lancet Primary Care 2026;2:100107.
And many more studies
Other peer-reviewed journals have also published studies about MONA, in diabetic retinopathy, diabetic maculopathy and glaucoma. Ask us for the full list of publications.